Sensorion Azione

Sensorion Debiti verso fornitori

Il Debiti Commerciali di Sensorion (ALSEN.PA) al 12 ago 2026 è 5,56 Mio. EUR. L'anno precedente, Debiti Commerciali era 6,91 Mio. EUR — una variazione del -19,45% (inferiore).

Debiti verso fornitori

5,56 Mio.EUR

YoY

-19,45%

Ultimo aggiornamento:

Debiti Commerciali di Sensorion ammonta a 2026 5,56 Mio. EUR. Debiti Commerciali di Sensorion ammontava a 2025 6,91 Mio. EUR. Diminuisce del -19,45% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Sensorion Analisi delle Azioni

Cosa fa Sensorion? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Sensorion azioni

Debiti Commerciali di Sensorion è 5,56 Mio. EUR nel 2026.

Il Debiti Commerciali di Sensorion è passato da 6,91 Mio. EUR a 5,56 Mio. EUR, con una variazione del -19,45 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Sensorion di Debiti Commerciali dal 2006, con valori annuali, grafici e analisi dettagliate.

I debiti commerciali rappresentano il denaro dovuto ai fornitori per beni e servizi ricevuti. È un componente fondamentale della gestione del capitale di esercizio.

Il EUR di Debiti Commerciali è un fattore chiave per gli investitori. I cambiamenti in questa metrica possono segnalare il miglioramento o il deterioramento dei fondamentali, impattando direttamente il prezzo delle azioni. Su Eulerpool puoi tracciare il Sensorion di Debiti Commerciali storicamente e in tempo reale.

Access this data via the Eulerpool API

Bilancio — Sensorion

Tutte le Metriche Finanziarie — Sensorion